Gallus to Manufacture Anti-PSMA mAb for Progenics Pharmaceuticals - - BioPharm International

ADVERTISEMENT

Gallus to Manufacture Anti-PSMA mAb for Progenics Pharmaceuticals


manufacturing organization announced that it has been selected by Progenics Pharmaceuticals to manufacture the anti-prostate specific membrane antigen (PSMA) monoclonal antibody used in Progenics’ PSMA ADC product candidate. Under the agreement the antibody will be produced in Gallus’ commercial manufacturing facility in St. Louis, Mo.

PSMA ADC is a fully human monoclonal antibody-drug conjugate designed to deliver chemotherapeutic drug selectively to prostate cancer cells. It does so by targeting the three-dimensional structure of PSMA, a protein that is a clinically validated biomarker of prostate cancer, which is expressed on the surface of prostate cancer cells. The PSMA antibody produced at Gallus is designed to internalize into the cancer cell, release active anti-cancer drug, and destroy the malignant cell.

Source: Gallus BioPharmaceucticals

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
Author Guidelines

Click here